Cargando…
The combined effect of epigenetic inhibitors for LSD1 and BRD4 alters prostate cancer growth and invasion
Epigenetic modifications play an important role in prostate tumor development and progression. Epigenetic drugs are emerging as effective modulators of gene expression that act on pathways potentially important in the control of cancer clinically. We investigated two different epigenetic modulating...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977660/ https://www.ncbi.nlm.nih.gov/pubmed/31901895 http://dx.doi.org/10.18632/aging.102630 |
_version_ | 1783490559017484288 |
---|---|
author | Wang, Jianlin Yu, Qian Qiu, Zhaoping Dai, Tao Wang, Shuxia Yang, Xiuwei Evers, B. Mark Wu, Yadi |
author_facet | Wang, Jianlin Yu, Qian Qiu, Zhaoping Dai, Tao Wang, Shuxia Yang, Xiuwei Evers, B. Mark Wu, Yadi |
author_sort | Wang, Jianlin |
collection | PubMed |
description | Epigenetic modifications play an important role in prostate tumor development and progression. Epigenetic drugs are emerging as effective modulators of gene expression that act on pathways potentially important in the control of cancer clinically. We investigated two different epigenetic modulating drugs, SP-2509 and JQ1, that target histone lysine demethylase 1 (LSD1), and bromodomain-containing protein (BRD), respectively and their combined effect in three different prostate cancer (PCa) types: 1) androgen receptor (AR)-positive and androgen-sensitive; 2) AR-positive but castration-resistant; and 3) androgen-nonresponsive. We found combined treatment provided a synergistic growth inhibition in castration-resistant PCa cells but knockdown of AR reduced sensitivity to both inhibitors in these cells. In the androgen-sensitive cell lines, AR knockdown attenuated sensitivity to the LSD1 inhibitor but not the JQ1 inhibitor. Strikingly, treatment with SP-2509 slightly, and JQ1 markedly increased invasion in PCa cells with high AR expression but decreased invasion in PCa cells with low/negative AR expression. Our results suggest that these two epigenetic drugs are novel and promising compounds for the development of PCa therapeutics, particularly for castration-resistant disease. However, due to the potential risks, including metastasis, caution must be exercised in the clinical setting. |
format | Online Article Text |
id | pubmed-6977660 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Impact Journals |
record_format | MEDLINE/PubMed |
spelling | pubmed-69776602020-01-31 The combined effect of epigenetic inhibitors for LSD1 and BRD4 alters prostate cancer growth and invasion Wang, Jianlin Yu, Qian Qiu, Zhaoping Dai, Tao Wang, Shuxia Yang, Xiuwei Evers, B. Mark Wu, Yadi Aging (Albany NY) Research Paper Epigenetic modifications play an important role in prostate tumor development and progression. Epigenetic drugs are emerging as effective modulators of gene expression that act on pathways potentially important in the control of cancer clinically. We investigated two different epigenetic modulating drugs, SP-2509 and JQ1, that target histone lysine demethylase 1 (LSD1), and bromodomain-containing protein (BRD), respectively and their combined effect in three different prostate cancer (PCa) types: 1) androgen receptor (AR)-positive and androgen-sensitive; 2) AR-positive but castration-resistant; and 3) androgen-nonresponsive. We found combined treatment provided a synergistic growth inhibition in castration-resistant PCa cells but knockdown of AR reduced sensitivity to both inhibitors in these cells. In the androgen-sensitive cell lines, AR knockdown attenuated sensitivity to the LSD1 inhibitor but not the JQ1 inhibitor. Strikingly, treatment with SP-2509 slightly, and JQ1 markedly increased invasion in PCa cells with high AR expression but decreased invasion in PCa cells with low/negative AR expression. Our results suggest that these two epigenetic drugs are novel and promising compounds for the development of PCa therapeutics, particularly for castration-resistant disease. However, due to the potential risks, including metastasis, caution must be exercised in the clinical setting. Impact Journals 2020-01-05 /pmc/articles/PMC6977660/ /pubmed/31901895 http://dx.doi.org/10.18632/aging.102630 Text en Copyright © 2020 Wang et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Wang, Jianlin Yu, Qian Qiu, Zhaoping Dai, Tao Wang, Shuxia Yang, Xiuwei Evers, B. Mark Wu, Yadi The combined effect of epigenetic inhibitors for LSD1 and BRD4 alters prostate cancer growth and invasion |
title | The combined effect of epigenetic inhibitors for LSD1 and BRD4 alters prostate cancer growth and invasion |
title_full | The combined effect of epigenetic inhibitors for LSD1 and BRD4 alters prostate cancer growth and invasion |
title_fullStr | The combined effect of epigenetic inhibitors for LSD1 and BRD4 alters prostate cancer growth and invasion |
title_full_unstemmed | The combined effect of epigenetic inhibitors for LSD1 and BRD4 alters prostate cancer growth and invasion |
title_short | The combined effect of epigenetic inhibitors for LSD1 and BRD4 alters prostate cancer growth and invasion |
title_sort | combined effect of epigenetic inhibitors for lsd1 and brd4 alters prostate cancer growth and invasion |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977660/ https://www.ncbi.nlm.nih.gov/pubmed/31901895 http://dx.doi.org/10.18632/aging.102630 |
work_keys_str_mv | AT wangjianlin thecombinedeffectofepigeneticinhibitorsforlsd1andbrd4altersprostatecancergrowthandinvasion AT yuqian thecombinedeffectofepigeneticinhibitorsforlsd1andbrd4altersprostatecancergrowthandinvasion AT qiuzhaoping thecombinedeffectofepigeneticinhibitorsforlsd1andbrd4altersprostatecancergrowthandinvasion AT daitao thecombinedeffectofepigeneticinhibitorsforlsd1andbrd4altersprostatecancergrowthandinvasion AT wangshuxia thecombinedeffectofepigeneticinhibitorsforlsd1andbrd4altersprostatecancergrowthandinvasion AT yangxiuwei thecombinedeffectofepigeneticinhibitorsforlsd1andbrd4altersprostatecancergrowthandinvasion AT eversbmark thecombinedeffectofepigeneticinhibitorsforlsd1andbrd4altersprostatecancergrowthandinvasion AT wuyadi thecombinedeffectofepigeneticinhibitorsforlsd1andbrd4altersprostatecancergrowthandinvasion AT wangjianlin combinedeffectofepigeneticinhibitorsforlsd1andbrd4altersprostatecancergrowthandinvasion AT yuqian combinedeffectofepigeneticinhibitorsforlsd1andbrd4altersprostatecancergrowthandinvasion AT qiuzhaoping combinedeffectofepigeneticinhibitorsforlsd1andbrd4altersprostatecancergrowthandinvasion AT daitao combinedeffectofepigeneticinhibitorsforlsd1andbrd4altersprostatecancergrowthandinvasion AT wangshuxia combinedeffectofepigeneticinhibitorsforlsd1andbrd4altersprostatecancergrowthandinvasion AT yangxiuwei combinedeffectofepigeneticinhibitorsforlsd1andbrd4altersprostatecancergrowthandinvasion AT eversbmark combinedeffectofepigeneticinhibitorsforlsd1andbrd4altersprostatecancergrowthandinvasion AT wuyadi combinedeffectofepigeneticinhibitorsforlsd1andbrd4altersprostatecancergrowthandinvasion |